Reported Earnings • Jun 01
Full year 2026 earnings released: EPS: ₹2.21 (vs ₹2.06 in FY 2025) Full year 2026 results: EPS: ₹2.21 (up from ₹2.06 in FY 2025). Revenue: ₹1.43b (up 7.5% from FY 2025). Net income: ₹55.2m (up 16% from FY 2025). Profit margin: 3.9% (up from 3.6% in FY 2025). The increase in margin was driven by higher revenue. Aankondiging • May 23
Ambey Laboratories Limited to Report Second Half, 2026 Results on May 29, 2026 Ambey Laboratories Limited announced that they will report second half, 2026 results on May 29, 2026 Valuation Update With 7 Day Price Move • Apr 24
Investor sentiment improves as stock rises 37% After last week's 37% share price gain to ₹37.05, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 2.2% over the past year. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹21.90, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 49% over the past year. Valuation Update With 7 Day Price Move • Feb 26
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹23.00, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 55% over the past year. New Risk • Jan 12
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹899.3m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Market cap is less than US$10m (₹899.3m market cap, or US$9.97m). Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹44.35, the stock trades at a trailing P/E ratio of 24.9x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 30% over the past year. New Risk • Dec 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₹1.08b market cap, or US$12.1m). New Risk • Nov 24
New major risk - Revenue and earnings growth Earnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Minor Risk Market cap is less than US$100m (₹1.05b market cap, or US$11.7m). Aankondiging • Nov 14
Ambey Laboratories Limited to Report First Half, 2026 Results on Nov 14, 2025 Ambey Laboratories Limited announced that they will report first half, 2026 results on Nov 14, 2025 Board Change • Oct 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Abdul Quadir is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Sep 08
Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024) Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.0% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses. Aankondiging • Sep 04
Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2025 Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2025, at 15:00 Indian Standard Time. Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹44.75, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 30x in the Chemicals industry in India. Total loss to shareholders of 45% over the past year. New Risk • Jun 09
New major risk - Financial position The company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (60% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹1.04b market cap, or US$12.1m). Reported Earnings • Jun 05
Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024) Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.2% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses. New Risk • Jun 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (76% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹1.01b market cap, or US$11.8m). New Risk • May 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). High level of non-cash earnings (76% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹948.0m market cap, or US$11.1m). Valuation Update With 7 Day Price Move • May 19
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹45.55, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 26x in the Chemicals industry in India. Reported Earnings • Nov 18
First half 2025 earnings released First half 2025 results: EPS: ₹0.16. Net income: ₹29.7m (up ₹29.7m from 1H 2024). New Risk • Sep 15
New major risk - Financial position The company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (54% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₹1.77b market cap, or US$21.1m). Aankondiging • Sep 13
Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2024 Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2024, at 13:00 Indian Standard Time. New Risk • Aug 23
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (53% net debt to equity). Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (₹1.96b market cap, or US$23.4m). Valuation Update With 7 Day Price Move • Aug 22
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹78.75, the stock trades at a trailing P/E ratio of 43x. Average trailing P/E is 35x in the Chemicals industry in India. Valuation Update With 7 Day Price Move • Aug 01
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹69.20, the stock trades at a trailing P/E ratio of 37.8x. Average trailing P/E is 35x in the Chemicals industry in India. Buy Or Sell Opportunity • Jul 23
Now 21% undervalued The stock has been flat over the last 90 days, currently trading at ₹76.85. The fair value is estimated to be ₹97.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last year. Earnings per share has declined by 64%. Aankondiging • Jul 11
Ambey Laboratories Limited has completed an IPO in the amount of INR 446.76 million. Ambey Laboratories Limited has completed an IPO in the amount of INR 446.76 million.
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 330,000
Price\Range: INR 68
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 1,868,000
Price\Range: INR 68
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 1,252,000
Price\Range: INR 68
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 936,000
Price\Range: INR 68
Security Name: Equity Shares
Security Type: Common Stock
Securities Offered: 2,184,000
Price\Range: INR 68
Transaction Features: Regulation S; Rule 144A Board Change • Jul 11
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Abdul Quadir is the most experienced director on the board, commencing their role in 2022. Independent Director Roni Soni was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. 